Everolimus exceeds sunitinib in pNET

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.647, 2012-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Everolimus

By Chapman T.M. Perry C.M.

Drugs, Vol. 64, Iss. 8, 2004-01 ,pp. : 861-872

Adis International

Access to resources Recommend Favorite

Sunitinib

By Deeks Emma D. Keating Gillian M.

Drugs, Vol. 66, Iss. 17, 2006-01 ,pp. : 2255-2266

Adis International

Access to resources Recommend Favorite

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

By Di Lorenzo Giuseppe Casciano Roman Malangone Elisabetta Buonerba Carlo Sherman Steven Willet Jacob Wang Xufang Liu Zhimei De Placido Sabino

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1491-1497

Informa Healthcare

Access to resources Recommend Favorite

Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

By Di Lorenzo Giuseppe Casciano Roman Malangone Elisabetta Buonerba Carlo Sherman Steven Willet Jacob Wang Xufang Liu Zhimei De Placido Sabino

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1079-1080

Informa Healthcare

Access to resources Recommend Favorite

Management of Metabolic Cytochrome P450 3A4 Drug-Drug Interaction between Everolimus and Azole Antifungals in a Renal Transplant Patient

By Billaud E.M. Antoine C.

Clinical Drug Investigation, Vol. 29, Iss. 7, 2009-06 ,pp. : 481-486

Adis International

Access to resources Recommend Favorite